Skip to main navigation Skip to search Skip to main content

In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae

  • Infection IMed, AstraZenecaPharmaceuticals LP
  • SUNY Downstate Health Sciences University

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

The in vitro activities of AZD0914, levofloxacin, azithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae were tested. For AZD0914, the MIC90s for C. trachomatis and C. pneumoniae were 0.25 μg/ml (range, 0.06 to 0.5 μg/ml) and 1 μg/ml (range, 0.25 to 1 μg/ml), respectively, and the minimal bactericidal concentrations at which 90% of the isolates were killed (MBC90s) were 0.5 μg/ml for C. trachomatis (range, 0.125 to 1 μg/ml) and 2 μg/ml for C. pneumoniae (range, 0.5 to 2 μg/ml).

Original languageEnglish
Pages (from-to)7595-7596
Number of pages2
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Dive into the research topics of 'In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae'. Together they form a unique fingerprint.

Cite this